2022
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Hudis CA, Winer EP, Partridge A, Hyslop T, Carey LA, Perou CM, Sikov WM. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal Of Clinical Oncology 2022, 40: 1323-1334. PMID: 35044810, PMCID: PMC9015203, DOI: 10.1200/jco.21.01506.Peer-Reviewed Original ResearchConceptsLong-term outcomesEvent-free survivalTriple-negative breast cancerResidual cancer burdenResidual diseaseImmune activationBreast cancerPathologic complete response rateRandomized phase II trialEnd pointSuperior long-term outcomesCox proportional hazards modelComplete response rateSecondary end pointsPhase II trialPretreatment tumor biopsiesKaplan-Meier methodOverall survival rateTumor-infiltrating lymphocytesLog-rank testPretreatment tumor samplesMinimal residual diseaseProportional hazards modelWeekly paclitaxelII trial
2010
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. Journal Of Clinical Oncology 2010, 28: 1145-1153. PMID: 20100965, PMCID: PMC2834466, DOI: 10.1200/jco.2009.22.4725.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBreast NeoplasmsCisplatinDNA MethylationDNA-Binding ProteinsFemaleGenes, BRCA1Genes, p53HumansMiddle AgedMutationNeoadjuvant TherapyNuclear ProteinsOligonucleotide Array Sequence AnalysisPromoter Regions, GeneticReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTumor Protein p73Tumor Suppressor ProteinsConceptsTriple-negative breast cancerBreast cancerSubset of TNBCCisplatin responseSporadic triple-negative breast cancerGood pathologic responsePathologic treatment responseSingle-agent cisplatinCycles of cisplatinStandard adjuvant chemotherapyPathologic complete responseSubset of patientsPredictors of responseBasal-like tumorsPretreatment tumor samplesBreast cancer treatmentHER2/neuBRCA1 promoter methylationBRCA1 mRNA expressionAdjuvant chemotherapyNeoadjuvant cisplatinNeoadjuvant trialsDefinitive surgeryGene expression signaturesPartial response